Translational Research in Maternal and Pediatric Pharmacology and Therapeutics (R21 Clinical Trial Optional)

The purpose of this funding opportunity announcement (FOA) is to encourage applications that will perform basic, translational and clinical research to (1) advance the understanding of underlying mechanisms of drug action; (2) discover and develop novel therapeutics; (3) enhance the usage of existing drugs or drug repurposing for safer and more effective treatment for pregnant women, lactating women, neonates and children. The overall goal is to improve drug safety and efficacy for maternal and pediatric precision therapeutics.

Application due date:December 10, 2021, April 11, 2022, August 10, 2022, December 9, 2022.

Estimated Total Program Funding: The combined budget for direct costs for the two-year project period may not exceed $275,000. No more than $200,000 in direct costs may be requested in any single year

Funder: National Institutes of Health (NIH), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), and Office of Research on Women’s Health (ORWH)